Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88
Inflammation · 2026
DOI: 10.1007/s10753-025-02423-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammation, 2026. Verfasst von Zhongqian Jin und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. Hauptthemen laut MEDLINE: Acute Lung Injury, Myeloid Differentiation Factor 88, Flavonoids, Anti-Inflammatory Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Funding of Zhejiang Province, Wenzhou Major Scientific and Technological Innovation Project.
Abstract (Originalsprache)
Acute lung injury (ALI), a severe respiratory syndrome driven by dysregulated inflammatory cascades, urgently requires novel therapeutic strategies. The activation of the MyD88 (Myeloid differentiation factor 88)-mediated TLR (Toll-like receptor) inflammatory signaling pathway plays a crucial role in the pathophysiology of ALI, while minimally involving interferon-mediated responses. Targeting MyD88 offers a promising approach for ALI drug development. Here, we employed surface plasmon resonance (SPR) and in vitro anti-inflammatory screening methods to evaluate the interaction of candidate drugs with MyD88 and their anti-inflammatory activity. This was followed by anti-inflammatory verification in lipopolysaccharide (LPS)-induced ALI mice. Our findings reveal that Fisetin, a flavonoid derived from Cotinus coggygria, exhibited the strongest MyD88-binding affinity and suppressed MyD88 homodimerization, thereby blocking downstream NF-κB and MAPK activation. In LPS-challenged mice, Fisetin significantly reduced pulmonary inflammatory levels, decreased lung wet/dry ratio, and attenuated neutrophil infiltration. In conclusion, Fisetin emerges as a novel MyD88 inhibitor that disrupts TLR-driven inflammatory amplification, positioning it as a phytotherapeutic candidate for ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
- School of Pharmaceutical Sciences, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. gaozhichen@wmu.edu.cn.
- School of Pharmaceutical Sciences, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China. gaozhichen@wmu.edu.cn.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. 632834681@qq.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Funding of Zhejiang Province
- Wenzhou Major Scientific and Technological Innovation Project
- Qianjiang Talent Plan of Zhejiang
Zitieren
APA
Jin, Z., Liu, X., Xie, Z., Xie, Y., Xu, K., Zhao, S., Zhou, Z., Qian, C., Jiang, Y., Lin, F., Liu, Y., Chen, R., Chen, G., & Wang, Y. (2026). Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88. Inflammation. https://doi.org/10.1007/s10753-025-02423-0
Vancouver
Jin Z, Liu X, Xie Z, Xie Y, Xu K, Zhao S, et al. Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88. Inflammation. 2026. doi:10.1007/s10753-025-02423-0
BibTeX
@article{Jin2026,
author = {Jin, Zhongqian and Liu, Xin and Xie, Zhuohui and Xie, Yuting and Xu, Kangmin and Zhao, Shengnan and Zhou, Zengxian and Qian, Chenghao and Jiang, Yuxiao and Lin, Fenfen and Liu, Yue and Chen, Ruping and Chen, Gaozhi and Wang, Yunjie},
title = {Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88},
journal = {Inflammation},
year = {2026},
doi = {10.1007/s10753-025-02423-0}
}
EUVIMED